Key Highlights
- Abbas Kazimi appointed as CEO and Board Member of Nimbus Therapeutics, effective immediately.
- Succeeds Jeb Keiper, MS, MBA, following a planned leadership transition.
- Kazimi played a pivotal role in securing over $7 billion in deals, including the TYK2 sale to Takeda.
- Nimbus advances drug discovery with its computational platform, focusing on oncology and autoimmune diseases.
- Continued industry validation, including its WRN and SIK inhibitor programs and collaborations with Lilly.
Source: Business Wire
Notable Quotes
- “We are excited to announce the next chapter in leadership at Nimbus. The board is unanimous in its support of Abbas… With the recent appointment of Peter Tummino as President of R&D, we are confident Abbas will continue to deliver on the company’s mission to bring breakthrough medicines to patients.” — Bruce Booth, D. Phil., Chairman of the Board and Co-Founder at Nimbus Therapeutics
- “After spending over a decade at Nimbus, I couldn’t be more proud of the incredible team we’ve built… I can think of no better leader than Abbas, who has led this team in creating an incredibly valuable biotech company.” — Jeb Keiper, Former CEO at Nimbus Therapeutics
- “I am honored to lead Nimbus at this pivotal time in the company’s evolution. Our robust pipeline… continues to validate our approach and strengthen our position in the industry.” — Abbas Kazimi, CEO at Nimbus Therapeutics
Why This Matters
This leadership transition at Nimbus Therapeutics marks a significant milestone for the company, as it continues to leverage computational drug discovery to develop breakthrough small molecule medicines. Under Kazimi’s leadership, Nimbus is well-positioned to advance its oncology and autoimmune drug pipeline and further its impact in biotech through strategic industry collaborations.
Related

Terremoto Biosciences Appoints Charles Baum as CEO
Key Highlights Charles Baum, M.D., Ph.D., appointed as Chief Executive Officer of Terremoto Biosciences.Baum succeeds Peter Thompson, who remains as Board chairperson.Baum’s previous leadership at Mirati Therapeutics led to significant pipeline value and a major acquisition.Terremoto focuses on developing highly targeted therapeutics for severe diseases.Baum’s extensive drug development experience includes…

Christian Howell Appointed CEO of Cognito Therapeutics
Key Highlights Christian Howell appointed CEO, succeeding Brent Vaughan Focus on commercialization of Alzheimer's therapy, Spectris™ Over 20 years of expertise in medical devices and healthcare innovation Source: Business Wire Notable Quotes “Christian is an exceptional strategic leader with a proven track record in medical device launches, and I look…
Sean A. MacDonald Appointed CEO of Domain Therapeutics
Key Highlights Sean A. MacDonald appointed as CEO, previously Chief Business Officer and Executive Strategic Advisor at Domain Therapeutics.Will lead Domain's Series B fundraising and expand its portfolio of GPCR-targeting cancer therapies.Has a strong background in business development and strategic planning across North America and Europe.Source: Business Wire Notable Quotes "2024…